Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2017

--Presentations to include late-breaker highlighting Endocyte's next generation CAR T-cell therapeutic platform—

WEST LAFAYETTE, Ind., March 27, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that eight posters will be presented by Endocyte scientists at the American Association for Cancer Research (AACR) Annual Meeting 2017 to be held in Washington, DC, April 1 - 5, 2017.

Key presentations during the meeting include a late-breaking poster presentation of new research from investigators and faculty at the Purdue University Center for Drug Discovery on the application of Endocyte's SMDC technology in a chimeric antigen receptor (CAR) therapy setting. Additionally, the company will present several posters with preclinical data relating to Endocyte’s SMDC technology, including developments in combination therapies and novel proPBD warheads.

The presentation materials will be available on Endocyte's website following presentation at the conference.

Presentations are as follows:

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Title</th>
<th>When</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2057</td>
<td>Evaluation of anti-tumor efficacy of EC1456 in low-passage and pre-treated patient-derived xenograft models of triple-negative breast cancer</td>
<td>Monday, April 3, 1 p.m. - 5 p.m. CDT</td>
<td>Drug Resistance: Other Topics</td>
<td>Halls A-C, Poster Section 3</td>
</tr>
<tr>
<td>2133</td>
<td>Pre-clinical studies of EC2629, a highly potent FR targeted DNA crosslinking agent</td>
<td>Monday, April 3, 1 p.m. - 5 p.m. CDT</td>
<td>New Targets 2</td>
<td>Halls A-C, Poster Section 6</td>
</tr>
<tr>
<td>LB-187</td>
<td>New methods for controlling CAR T-cell mediated cytokine storms</td>
<td>Tuesday, April 4, 8 a.m. - 12 p.m. CDT</td>
<td>Late-Breaking Research: Immunology</td>
<td>Poster Section 35</td>
</tr>
<tr>
<td>3670</td>
<td>Treatment of epithelial ovarian cancer with folate receptor (α/β) targeted chemotherapy is enhanced by CTLA-4 blockage: Learning from animal models</td>
<td>Tuesday, April 4, 8 a.m. - 12 p.m. CDT</td>
<td>Dendritic Cells as Critical Immune Targets</td>
<td>Halls A-C, Poster Section 27</td>
</tr>
<tr>
<td>3228</td>
<td>Development and characterization of in vitro assays to detect and quantitate tubulysin B hydrazide in biological samples</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
About Endocyte's SMDC Bi-Specific Adaptors

Endocyte's SMDC bi-specific adaptors represent a novel approach that makes possible the engineering of a single universal CAR T-cell, designed to bind with high affinity to fluorescein isothiocyanate (FITC). This universal CAR T-cell can be specifically directed to cancer cells through the administration of a tumor targeted FITC-containing SMDC, known as a bi-specific adaptor that acts to bridge the universal CAR T-cell with the cancer cells to cause localized T-cell activation. This approach has been shown pre-clinically to address three key CAR T-cell issues by: (i) avoiding hyper-activation of CAR T-cells leading to a cytokine storm, (ii) enabling termination of CAR T-cell activity upon eradication of the tumor, and (iii) potentially enabling elimination of all cancer cells in heterogeneous solid tumors. In March 2017, Endocyte entered into a research collaboration with Seattle Children's Research Institute and Dr. Michael Jensen for the development of Endocyte's SMDC platform in the chimeric antigen receptor T-cell (CAR T-cell) immunotherapy setting through the use of Endocyte's proprietary SMDC bi-specific adaptor molecules.

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte's website at www.endocyte.com.

Contacts:

Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com

Source: Endocyte, Inc.